



Introduction: The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion of the hormonally inactive cortisone 
to active cortisol, thus facilitating glucocorticoid receptor activation in target tissues. Increased expression of 11β-HSD1 in adipose tissue has been 
associated with obesity and insulin resistance. In this study, we investigated the association of two 11β-HSD1 gene (HSD11B1) polymorphisms with 
the metabolic syndrome (MetS) and its characteristics in the Bosnian population.
Materials and methods: The study included 86 participants: 43 patients diagnosed with MetS and 43 healthy controls. Subjects were genotyped 
for two HSD11B1 gene polymorphisms: rs846910: G>A and rs45487298: insA, by the high resolution melting curve analysis. Genotype distribution 
and an infl uence of genotypes on clinical and biochemical parameters were assessed.
Results: There was no signifi cant diff erence in the mutated allele frequencies for the two HSD11B1 gene polymorphisms between MetS patients 
and controls. In MetS patients, no signifi cant associations between disease-associated traits and rs45487298: insA were found. Regarding rs846910: 
G>A variant, heterozygous patients (G/A) had signifi cantly lower systolic (P = 0.017) and diastolic blood pressure (P = 0.015), lower HOMA-IR index 
(P = 0.011) and higher LDL-cholesterol levels (P = 0.049), compared to the wild-type homozygotes. In the control group, rs45487298: insA polymor-
phism was associated with lower fasting plasma insulin levels (P = 0.041), lower homeostasis model assessment insulin resistance (HOMA-IR) index 
(P = 0.041) and lower diastolic blood pressure (P = 0.048). Signifi cant diff erences between rs846910: G>A genotypes in controls were not detected. 
Haplotype analysis confi rmed the association of rs45487298: insA with markers of insulin resistance in the control subjects.
Conclusions: Our results indicate that a common rs45487298: insA polymorphism in HSD11B1 gene may have a protective eff ect against insulin 
resistance.
Key words: metabolic syndrome; insulin resistance; obesity; 11-beta-hydroxysteroid dehydrogenase type 1; polymorphism, genetic; high resoluti-
on melting curve analysis
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The metabolic syndrome (MetS) represents a clus-
ter of metabolic disorders including abdominal 
obesity, dyslipidemia (elevated triglycerides and 
lowered high-density lipoprotein cholesterol (HDL-
cholesterol)), hyperglycemia and hypertension (1). 
These metabolic abnormalities are associated with 
increased risk for cardiovascular disease and type 
2 diabetes mellitus (2,3). It is estimated that about 
20-30% of the world’s adult population has MetS 
(3). Diagnostic criteria for MetS have changed dur-
ing the last decade with new insights into the 
pathogenesis of disease. Diff erent health organi-
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zations had proposed their own criteria and fi nally 
in 2009, a new harmonized defi nition was accept-
ed (1). MetS is diagnosed when any three of the 
following fi ve criteria are met: increased waist cir-
cumference (with population- and country-specif-
ic cut points), triglycerides of at least 150 mg/dL (≥ 
1.7 mmol/L), HDL-cholesterol less than 40 mg/dL 
(< 1.0 mmol/L) in males and less than 50 mg/dL (< 
1.3 mmol/L) in females, blood pressure of at least 
130/85 mmHg and fasting glucose of at least 100 
mg/dL (≥ 5.6 mmol/L) (1). Recommended waist cir-
cumference thresholds for Europids are ≥ 94 cm 
for men and ≥ 80 cm for women (1). Abdominal 
obesity and physical inactivity are considered as 
major causes for MetS. Beside this, genetic factors, 
aging and endocrine disorders, all contribute to 
the susceptibility for disease (2).
The enzyme 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1) catalyzes the conversion of the 
hormonally inactive cortisone to active cortisol, 
thus facilitating glucocorticoid receptor activation 
in target tissues. It is a microsomal, nicotinamide 
adenine dinucleotide-dependent dehydrogenase, 
identifi ed in many tissues, with highest levels of 
expression in the liver, gonads, adipose tissue, and 
brain (4). The similarities between Cushing’s syn-
drome and MetS lead to the hypothesis that in-
creased cortisol concentrations in adipose tissue 
are implicated in the pathogenesis of visceral 
obesity and MetS. A transgenic mouse overex-
pressing 11β-HSD1 in adipose tissue, became a 
model for MetS with increased visceral fat mass, 
glucose intolerance, insulin resistance, dyslipi-
demia and hypertension (5). In contrast, 11β-HSD1 
knockout mice, showed improved insulin sensitivi-
ty and lipid profi le (6). Various studies (7-16), al-
though not all (17), have reported increased 11β-
HSD1 expression in subcutaneous adipose tissue 
in obese subjects. Some of them confi rmed this 
association also in visceral adipose depots (7,11,16), 
while others did not (9,18,19). Several researches 
found positive correlations of 11β-HSD1 subcuta-
neous fat expression with markers of insulin resist-
ance (10,12,14,15,18,19). Investigations in animal 
models and early results of human studies suggest 
that inhibitors of 11β-HSD1 are promising thera-
peutic drugs for obesity and diabetes (20), further 
supporting the role of 11β-HSD1 in the pathogen-
esis of MetS (21).
The gene encoding 11β-HSD1 (HSD11B1) is located 
on chromosome 1q32-q41. Several studies investi-
gated associations of single-nucleotide polymor-
phisms (SNPs) of HSD11B1 with metabolic pheno-
type. Two SNPs within HSD11B1 gene (rs846910: 
G>A and rs12086634: G>T) have been associated 
with type 2 diabetes in Pima Indians (15). SNP 
rs846910: G>A was also associated with hyperten-
sion (22). Another polymorphism, insertion of ade-
nine in intron 3 (rs45487298: insA), was associated 
with obesity and insulin resistance in children (23). 
On the contrary, Robitaille et al. found no associa-
tion of three HSD11B1 gene variants with compo-
nents of the MetS (24). Four other HSD11B1 poly-
morphisms were not associated with type 2 diabe-
tes or metabolic parameters in Koreans (25).
This is the fi rst study performed in population 
from Bosnia and Herzegovina, in which we exam-
ined a signifi cance of genetic variations in the 
HSD11B1 gene (rs846910: G>A and rs45487298: 
insA), in the pathogenesis of MetS. Infl uence of 




The study included a total of 86 participants from 
Bosnia and Herzegovina: 43 patients of General 
Hospital Tesanj, Zenica-Doboj Canton, diagnosed 
with MetS, and 43 healthy subjects. All research in-
volving human subjects was done in accordance 
with the ethical recommendations and practices 
of the General Hospital Tesanj, and compiled with 
ethical principles of the Declaration of Helsinki. 
The study was approved by Ethics Committee of 
Cantonal Hospital Zenica and by the Institute for 
Genetic Engineering and Biotechnology, Universi-
ty of Sarajevo. Written informed consents were 
obtained for each participant involved in the study. 
MetS was diagnosed according to harmonized cri-
teria from 2009 that include three or more of the 
following abnormalities: waist circumference ≥ 94 
cm in men or ≥ 80 cm in women, triglycerides ≥ 
Biochemia Medica 2012;22(1):76–85
78
Dujic T. et al. HSD11B1 polymorphisms and metabolic syndrome
1.7 mmol/L (or specifi c treatment for this lipid ab-
normality), HDL-cholesterol < 1.0 mmol/L in men 
or < 1.3 mmol/L in women (or specifi c treatment 
for this lipid abnormality), blood pressure ≥ 130/85 
mmHg (or treatment for previously diagnosed hy-
pertension) and fasting glucose ≥ 5.6 mmol/L (or 
previously diagnosed type 2 diabetes) (1). Patients 
with an acute infection and/or infl ammation, en-
docrine disorders and those on insulin therapy 
were excluded from the study. Only 9 patients did 
not receive any therapy; 47% of all patients were 
treated with lipid-lowering drugs, 58% were treat-
ed with glucose-lowering drugs, and 74% received 
antihypertensive therapy. Control group consisted 
of 43 age-matched, healthy, non-obese subjects 
who had less than three features of MetS, and were 




Height, weight, waist circumference, systolic and 
diastolic blood pressure were measured in all sub-
jects. Waist circumference was measured at the 
midpoint between the lowest rib and the iliac crest 
(26). After overnight fast, blood samples were col-
lected for the determination of following bio-
chemical markers: insulin, glucose, total cholester-
ol, HDL-cholesterol, low-density lipoprotein cho-
lesterol (LDL-cholesterol), triglycerides, glycohe-
moglobin (HbA1c) and C-reactive protein (CRP). 
Whole blood with EDTA was used for HbA1c deter-
mination and serum was used for all other meas-
urements. Fasting insulin levels were measured by 
immunoenzymometric assay on an AxSYM analyz-
er (Abbott Laboratories, Abbott Park, IL, USA). 
HbA1c was determined by NGSP certifi ed method 
based on affi  nity separation, using the NycoCard 
reader (Axis-Shield, Oslo, Norway). Other markers 
were determined by standard methods with the 
use of autoanalyzer VITROS 350 Chemistry System 
(Ortho-Clinical Diagnostic, Rochester, New York, 
USA). The homeostasis model assessment insulin 
resistance index (HOMA-IR) was calculated using 
the formula: fasting insulin (mU/L) x fasting glu-
cose (mmol/L) /22.5 (27).
Genetic analyses
Genomic DNA was isolated from peripheral blood 
using Miller’s protocol (28). Two HSD11B1 gene pol-
ymorphisms, rs846910: G>A and rs45487298: insA, 
were genotyped by previously described high-res-
olution melting (HRM) method (29). HRM analysis 
was performed on the LightCycler®480 Real-Time 
PCR System (Roche Diagnostics GmbH, Mannheim, 
Germany). Briefl y, DNA fragments containing the 
analyzed polymorphisms were amplifi ed using the 
following primers and probes: F: 5’- CTC TGT TGC 
TTG TGC TTG ATT C-3’, R: 5’-AGA GCA GGC TTT CAG 
CAG ATA C-3’ and unlabeled probe: 5’-CTGGT-
GGGAATGATCAAATCAGAGAGA-3’ for rs846910: 
G>A, and F: 5’-GGT GAG GCT GTT TCT CTT ACC T-3’, 
R: 5’-GGT TGA TAC CTT TCC CAT TCT-3’ and unla-
beled probe: 5’-GGT CAC CAA GAG CTT TTG GGA 
GG-3’ for rs45487298: insA. The amplifi cation pro-
tocol consisted of initial denaturation at 95 °C for 
10 min and 60 cycles with denaturation at 95 °C for 
10 s, then 10 s annealing with a touchdown proto-
col covering a range of annealing temperatures 
from 68 to 58 °C (decreasing 1 °C per cycle) and 
elongation at 72 °C for 10 s. After amplifi cation, 
PCR products were denatured at 95 °C for 1 min 
and cooled to 40 °C. High resolution melting was 
performed by heating from 55 °C to 90 °C with 25 
acquisitions per 1 °C.
During each run, two positive control samples for 
each genotype and one negative control were 
used for quality control. Positive controls were pre-
viously confi rmed by PCR-RFLP method (29). Twen-
ty percent of all samples were double-genotyped 
with 100% concordant results.
Statistical analysis
Statistical analysis was performed using SPSS Sta-
tistics 17.0 software. A P value ≤ 0.05 was consid-
ered statistically signifi cant. The diff erences in 
genotype frequencies between study groups were 
analyzed by chi-square (χ2) test and Fisher’s exact 
test (in the case where expected frequencies were 
less or equal to 5). Genotype association with clini-
cal and biochemical markers was tested by Mann-
Whitney test (data did not follow normal distribu-
tion). Linkage disequilibrium between two poly-
morphisms was calculated by 2LD program (30). 
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Haplotype analyses were performed using PHASE 
2.1 software (31).
Power analysis was performed using the Quanto 




Clinical and biochemical variables of MetS patients 
and controls are presented in Table 1. Most of the 
measured anthropometric, hemodynamic and 
metabolic parameters were signifi cantly diff erent 
between the two groups except for total and LDL-
cholesterol concentration (Table 1).
Allele and genotype frequencies for rs846910: G>A 
and rs45487298: insA variants are presented in Ta-
ble 2. As the rs846910: G>A polymorphism is rare, 
there were no homozygous mutant genotypes 
(A/A). There was no signifi cant deviation from the 
Hardy-Weinberg equilibrium in two groups of sub-
jects studied, with respect to both polymorphisms 
Distribution of genotypes did not diff er signifi -
cantly between controls and MetS patients (Table 
2). However, the study had limited power to detect 
potentially small eff ects of these variants on MetS, 
which is multifactorial and very complex disease. 
The power of the study to detect odds ratios (ORs) 
between 1.2 and 2.0 at α = 0.05 was only 6-24% for 
rs846910: G>A (dominant model), and 7-33% for 
rs45487298: insA variant (recessive model). To de-
tect eff ect sizes of OR = 1.2-2.0, sample sizes of 
nearly 200-3200 and 150-2000 subjects in each 
group would be required, for rs846910: G>A and 
rs45487298: insA polymorphism, respectively.
Clinical and metabolic characteristics of patients 
with MetS according to the genotypes of rs846910: 
G>A and rs45487298: insA polymorphisms are 
shown in Table 3. No signifi cant associations be-
tween disease-associated traits and rs45487298: 
insA were found. Regarding rs846910: G>A variant, 
heterozygous patients (G/A) had signifi cantly low-
er systolic (P = 0.017) and diastolic blood pressure 




(N = 43) P
Age (years) 49 (40-56) 45 (41-51) 0.206
Males/Females 19/24 10/33 0.040
BMI (kg/m2) 33.0 (29.2-35.5) 24.7 (22.2-27.4) <0.001
Waist circumference (cm) 110 (96-120) 83 (78-90) <0.001
Systolic BP (mm Hg) 143 (130-158) 120 (110-125) <0.001
Diastolic BP (mm Hg) 90 (80-100) 78 (70-80) <0.001
Fasting insulin (mU/L) 10.6 (8.0-13.9) 7.3 (6.4-10.1) 0.010
Fasting glucose (mmol/L) 8.4 (5.5-11.7) 5.0 (4.7-5.2) <0.001
HOMA-IR 4.1 (2.7-6.1) 1.6 (1.4-2.3) <0.001
HbA1c (mmol/mol) 43 (37-55) 38 (29-42) <0.001
Total cholesterol (mmol/L) 5.6 (5.1-6.3) 5.8 (5.2-6.5) 0.385
LDL-cholesterol (mmol/L) 3.20 (2.60-4.01) 3.37 (2.87-4.19) 0.133
HDL-cholesterol (mmol/L) 1.07 (0.88-1.30) 1.67 (1.38-1.87) <0.001
Triglycerides (mmol/L) 2.26 (1.77-3.27) 1.17 (0.76-1.45) <0.001
hsCRP (mg/L) 5.0 (3.0-6.0) 1.3 (0.8-4.0) <0.001
Values represent medians (lower-upper quartile). BMI – body mass index; BP – blood pressure; HOMA-IR – 
homeostasis model assessment insulin resistance index; LDL – low-density lipoprotein; HDL – high-density 
lipoprotein; hsCRP – high-sensitivity C-reactive protein. All diff erences were tested using Mann-Whitney test.
TABLE 1. Clinical and biochemical characteristics of MetS patients and controls.
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InsA/InsA (N = 15)
Age (years) 52 (40-56) 45 (36-47) 0.154 51 (40-54) 49 (40-56) 0.925
BMI (kg/m2) 33.0 (29.4-36.1) 30.0 (26.5-34.3) 0.331 33.0 (27.3-36.5) 30.8 (29.8-35.5) 0.989
Waist circumference (cm) 110 (102-121) 96 (88-121) 0.265 110 (96-121) 110 (96-116) 0.790
Systolic BP (mm Hg) 145 (140-160) 130 (120-140) 0.017 140 (140-160) 140 (130-150) 0.403
Diastolic BP (mm Hg) 90 (80-100) 80 (70-90) 0.015 90 (80-105) 90 (80-95) 0.344
Fasting insulin (mU/L) 10.9 (8.1-14.1) 9.6 (8.0-10.6) 0.272 10.2 (7.6-14.1) 10.9 (8.1-13.9) 0.713
Fasting glucose (mmol/L) 8.6 (5.9-12.0) 5.6 (4.6-9.4) 0.063 8.5 (5.5-12.2) 6.8 (5.0-9.9) 0.171
HOMA-IR 4.6 (3.3-7.7) 2.5 (2.1-3.7) 0.011 4.0 (2.7-7.8) 4.1 (3.1-4.8) 0.563
HbA1c (mmol/mol) 43 (37-56) 41 (37-48) 0.483 42 (37-55) 43 (22-53) 0.649
Total cholesterol (mmol/L) 5.7 (5.1-6.2) 6.0 (4.8-7.5) 0.398 5.6 (5.1-6.2) 5.7 (5.0-6.4) 0.872
LDL-cholesterol (mmol/L) 3.10 (2.59-3.87) 4.35 (2.98-5.42) 0.049 3.21 (2.64-4.11) 3.11 (2.77-3.69) 0.863
HDL-cholesterol (mmol/L) 1.04 (0.88-1.39) 1.11 (0.88-1.23) 0.985 1.00 (0.86-1.28) 1.19 (0.96-1.66) 0.150
Triglycerides (mmol/L) 2.36 (2.00-3.85) 1.72 (1.69-2.96) 0.113 2.38 (1.96-3.42) 1.88 (1.70-2.41) 0.187
hsCRP (mg/L) 4.5 (3.0-6.0) 5.3 (1.0-7.0) 0.894 4.0 (3.0-5.7) 6.0 (2.3-8.5) 0.312
Values represent medians (lower-upper quartile). BMI – body mass index; BP – blood pressure; HOMA-IR – homeostasis model assessment insulin 
resistance index; LDL – low-density lipoprotein; HDL – high-density lipoprotein; hsCRP – high-sensitivity C-reactive protein. All diff erences were 




N (%) Mutatedallele frequency N (%)
Mutated
allele frequency
rs846910: G>A G/G 35 (83.3%)
0.08
34 (79.1%)
0.10 0.615G/A 7 (16.7%) 9 (20.9%)
A/A 0 (0%) 0 (0%)
Total 42 43
P2 0.841 0.745
rs45487298: insA N/N3 26 (63.4%)
0.20
25 (58.1%)
0.23 0.930N/insA 14 (34.1%) 16 (37.2%)
insA/insA 1 (2.4%) 2 (4.7%)
Total 41 43
P2 0.856 0.962
1signifi cance of χ2 / Fisher’s exact test for comparison of genotype frequencies between MetS patients and controls. 2 P-value for Hardy-Weinberg 
equilibrium. 3 N – wild-type allele of rs45487298: insA.
TABLE 2. Genotype and variant allele frequencies for rs846910: G>A and rs45487298: insA polymorphisms. 
TABLE 3. Comparison of clinical and biochemical characteristics between diff erent genotypes of rs846910: G>A and rs45487298: insA 
polymorphisms in the MetS patients group.
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higher LDL-cholesterol levels (P = 0.049), compared 
to the wild-type homozygotes.
Comparisons of clinical and metabolic parameters 
between genotypes in the control group are 
shown in Table 4. The carriers of rs45487298: insA 
polymorphism had signifi cantly lower fasting plas-
ma insulin (P = 0.041), lower HOMA-IR index (P = 
0.041), and lower diastolic blood pressure (P = 
0.048), compared to the wild-type homozygotes 
(Table 4). Signifi cant diff erences between rs846910: 
G>A genotypes in control subjects were not de-
tected (Table 4).
In addition, the haplotype analysis was also per-
formed. The rs846910: G>A and rs45487298: insA 
polymorphisms were in moderate linkage disequi-
librium (D’ = 0.418). Reconstructed haplotype and 
diplotype frequencies are shown in Table 5. There 
was no signifi cant diff erence in distribution of hap-
lotype frequencies between MetS patients and 
controls (P = 0.90). As AN and AInsA haplotypes 
were rare, only the associations of GN and GInsA 
haplotypes with clinical and biochemical markers 
were tested. By comparing the eff ects of GN/GInsA 
and GInsA/GInsA diplotypes together, to complete 
wild-type diplotype, we examined the potential 
eff ect of the InsA polymorphism solely (without 
rs846910: G>A). In MetS patients group, signifi cant 
associations were not found (data not shown). In 
the control group, analysis confi rmed the above 
mentioned results: carriers of GN/GInsA and GIn-
sA/GInsA diplotypes, as compared to GN/GN indi-
viduals, had lower fasting insulin level (data pre-
sented as median (1st-3rd quartile): 8.1 (7.0-13.9) mU/L 
vs. 6.2 (4.7-7.1) mU/L; P = 0.011) and lower HOMA-IR 
index (1.8 (1.4-2.8) vs. 1.3 (0.9-1.6); P = 0.016).
For continuous traits, the study had only 25% and 
34% power to detect moderate eff ect sizes of 0.5 at 
the α level 0.05, for rs846910: G>A and rs45487298: 
insA variants, respectively. Sample sizes of 200 and 
140 subjects would be needed to detect eff ect sizes 
of 0.5 with 80% power, for rs846910: G>A and 











InsA/InsA (N = 18)
Age (years) 45 (41-52) 46 (45-49) 0.756 46 (41-52) 45 (42-50) 0.705
BMI (kg/m2) 24.8 (21.4-28.5) 23.3 (22.4-26.3) 0.958 24.5 (22.3-28.5) 24.8 (21.5-26.9) 0.707
Waist circumference (cm) 83 (78-90) 83 (82-91) 0.565 82 (78-90) 85 (78-91) 0.802
Systolic BP (mm Hg) 120 (110-130) 120 (120-125) 0.780 120 (120-130) 120 (110-125) 0.137
Diastolic BP (mm Hg) 79 (70-80) 75 (70-85) 0.914 80 (75-84) 75 (70-80) 0.048
Fasting insulin (mU/L) 7.3 (6.3-10.5) 6.9 (5.7-8.8) 0.535 7.4 (6.9-11.6) 6.6 (5.5-7.1) 0.041
Fasting glucose (mmol/L) 4.9 (4.5-5.2) 5.0 (4.8-5.3) 0.483 5.0 (4.7-5.2) 4.9 (4.5-5.4) 0.685
HOMA-IR 1.6 (1.3-2.5) 1.5 (1.3-2.0) 0.564 1.7 (1.4-2.7) 1.4 (1.2-1.6) 0.041
HbA1c (mmol/mol) 38 (27-42) 39 (32-41) 0.899 38 (27-42) 38 (30-41) 0.978
Total cholesterol (mmol/L) 5.6 (5.1-6.5) 6.3 (5.8-7.0) 0.086 5.7 (5.0-6.3) 6.1 (5.3-6.8) 0.191
LDL-cholesterol (mmol/L) 3.20 (2.84-4.09) 4.19 (3.26-5.15) 0.055 3.37 (2.87-4.09) 3.51 (2.93-4.57) 0.808
HDL-cholesterol (mmol/L) 1.70 (1.41-1.87) 1.48 (1.29-1.90) 0.337 1.62 (1.39-1.81) 1.74 (1.37-1.98) 0.588
Triglycerides (mmol/L) 1.08 (0.78-1.39) 1.27 (0.67-1.56) 0.588 1.08 (0.85-1.32) 1.32 (0.67-1.94) 0.416
hsCRP (mg/L) 1.3 (0.8-4.3) 1.2 (0.9-1.9) 0.731 1.6 (0.8-4.0) 1.2 (0.8-2.1) 0.454
Values represent medians (lower-upper quartile). BMI – body mass index; BP – blood pressure; HOMA-IR – homeostasis model assessment insulin 
resistance index; LDL – low-density lipoprotein; HDL – high-density lipoprotein; hsCRP – high-sensitivity C-reactive protein. All diff erences were 
tested using Mann-Whitney test. 
TABLE 4. Comparison of clinical and biochemical characteristics between diff erent genotypes of rs846910: G>A and rs45487298: insA 
polymorphisms in the control group.
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Discussion
A number of studies have investigated an associa-
tion of 11β-HSD1 with obesity and insulin resist-
ance in humans. Most of them demonstrated a 
correlation of adipose HSD11B1 expression with 
obesity (7-16). Lindsay et al. (14) reported a positive 
correlation of 11β-HSD1 activity with measures of 
adiposity, fasting plasma glucose, insulin, and in-
sulin resistance by the homeostasis model. Anoth-
er study did not fi nd relationship between 11β-
HSD1 and insulin sensitivity (33). The role of 11β-
HSD1 in the pathogenesis of visceral obesity and 
insulin resistance has been corroborated by exper-
imental studies with enzyme inhibitors. However, 
several studies which explored the relationship 
between HSD11B1 polymorphisms, obesity and 
type 2 diabetes, gave confl icting results.
In this study, we did not fi nd the association of two 
investigated HSD11B1 gene polymorphisms, 
rs846910: G>A in 5’ upstream region and 
rs45487298: insA in intron 3, with MetS in a sample 
of Bosnian population. However, our study was 
preliminary and of limited statistical power due to 
the insuffi  cient sample size. Our negative fi ndings 
possibly refl ect statistical type 2 errors and the role 
of investigated genetic variants in MetS risk can-
not be ruled out. Analysis of anthropometric and 
biochemical markers in regards to the genotypes 
of rs846910: G>A showed signifi cant associations 
of the mutated A allele with lower systolic (P = 
0.017) and diastolic blood pressure (P = 0.015), low-
er HOMA-IR index (P = 0.011) and higher LDL-cho-
lesterol levels (P = 0.049) in patients with MetS. 
These results might refl ect the infl uence of 
rs846910: G>A variant on metabolic control in 
MetS patients. However, majority of patients in our 
cohort received therapy and therefore, these asso-
ciations have to be taken with particular caution. 
In the control group, rs846910: G>A did not show 
any signifi cant associations. Since this allele was 
rare, we could not confi rm these results by haplo-
type analysis . Only a few studies have examined 
the eff ect of rs846910: G>A on the metabolic phe-
notypes. In a study of Pima Indians, mutated A al-
lele was associated with type 2 diabetes and high-
er fasting insulin concentrations in healthy sub-
jects, independently of obesity (15). In another 
study, also in Pima Indians, rs846910: G>A was as-
sociated with hypertension, although these eff ects 
were modifi ed by birth era of subjects (22). How-
ever, in a recent study, no eff ect of rs846910: G>A 
variation on HSD11B1 promoter activity in vitro was 
found (34), suggesting that this polymorphism 
may not have direct functional consequences on 
the 11β-HSD1 activity in vivo.
Analysis of rs45487298: insA polymorphism, 
showed a signifi cant association between the vari-
ant allele and lower fasting plasma insulin levels (P 
= 0.041), lower HOMA-IR index (P = 0.041), and low-
er diastolic blood pressure (P = 0.048), in the con-
trol group. In MetS patients group, no signifi cant 
associations were observed. Haplotype analysis 
confi rmed benefi cial eff ect of rs45487298: insA on 
markers of insulin resistance in controls with even 
higher signifi cance (P = 0.011 for fasting plasma in-
sulin and P = 0.016 for HOMA-IR). This polymor-
phism, as well as another SNP in intron 3, located 





MetS patients Controls MetS patients Controls
GN2 0.758 0.717 GN/GN 0.571 0.535
GInsA 0.159 0.178 GN/GInsA 0.262 0.209
AN 0.047 0.062 GN/AN 0.071 0.070
AInsA 0.036 0.043 GN/AInsA 0.071 0.140
GInsA/GInsA 0 0.047
GInsA/AInsA 0.024 0
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40 bp downstream, rs12086634: T>G, reduce 
HSD11B1 transcriptional activity 2.5 x in vitro (35). 
These two mutations are in 100% linkage disequi-
librium. Interestingly, in the above mentioned 
study of Pima Indians, the wild-type allele of 
rs12086634: T>G was associated with type 2 diabe-
tes (15). It was also associated with higher insulin-
mediated glucose disposal rate (15). The authors 
suggest that the mechanism of association with 
markers of insulin resistance, independently of 
obesity, could be modulation of 11β-HSD1 expres-
sion in pancreatic beta cells, that is, a tissue-specif-
ic regulation of HSD11B1 (15). On the contrary, in a 
study sample of healthy overweight and normal 
weight children from diff erent racial backgrounds, 
mutated homozygotes for rs45487298: insA had 
greater BMI, waist circumference and insulin resist-
ance indices than heterozygote or wild-type chil-
dren (23). Although no signifi cant diff erences were 
found between the heterozygote and wild-type 
children in this study, heterozygotes had actually 
the lowest BMI, waist circumference, insulin con-
centration, and HOMA-IR index (23). This is partial-
ly in accordance with our results. Since there were 
only 2 homozygous mutant subjects in our study, 
we were not able to diff erentiate between the ef-
fects of mutated hetero- and homozygotous state 
on phenotype.
Robitaille et al. showed no association of 
rs45487298: insA and rs12086634: T>G polymor-
phisms with MetS in French-Canadian men (24). 
Variants were not associated with components of 
the MetS, except for higher plasma apolipoprotein 
B levels (24). Several other studies found also no 
association of rs45487298: insA or rs12086634: T>G 
with metabolic characteristics (36-39).
As mentioned above, cohort of several hundreds 
of subjects, depending on variant allele frequency, 
would be required to detect moderate eff ect sizes 
of two analyzed HSD11B1 polymorphisms, and 
thousands of individuals would be needed to de-
tect potentially small contributions of these vari-
ants to the complex phenotype of MetS. In gener-
al, many genetic association studies fail to repli-
cate initial positive fi ndings (40). Quality of these 
investigations depends on methodological issues 
related to phenotyping and genotyping, and is-
sues related to the study design (40). The key de-
terminant of the quality and the most critical issue 
is the sample size (40,41). Beside this, the proper 
defi nition of phenotype/disease is essential for the 
quality of a genetic association study (40). This is 
especially important for studies of MetS, since cri-
teria for diagnosis were changing throughout the 
last decade and population of MetS patients rep-
resent very heterogeneous group.
The results of our preliminary study indicated a 
positive eff ect of rs45487298: insA variation on 
blood pressure and markers of insulin sensitivity in 
the control group. However, these positive fi nd-
ings have to be replicated in a larger cohort of sub-
jects. Several genetic association studies per-
formed so far, yielded inconsistent results. The dis-
crepancy might be also attributed to the ethnic 
and environmental diff erences between studied 
cohorts. Furthermore, other, yet unidentifi ed ge-
netic variants in HSD11B1 gene or mutations in 
H6PD, the gene encoding the hexose-6-phosphate 
dehydrogenase (enzyme needed for 11β-HSD1 re-
ductase activity), can also infl uence expression or 
activity of 11β-HSD1. Nonetheless, the role of 11β-
HSD1 in insulin sensitivity and obesity seems to be 
complex and may be explained by its tissue-spe-
cifi c expression patterns.
In conclusion, this is the fi rst study performed in 
population from Bosnia and Herzegovina, in which 
a signifi cance of genetic variations of HSD11B1 
gene was investigated in the pathogenesis of met-
abolic syndrome. We found a signifi cant associa-
tion between rs45487298: insA, HSD11B1 gene pol-
ymorphism, and lower fasting plasma insulin and 
HOMA-IR index, as measures of insulin resistance 
in the control subjects. However, associations of 
this SNP with BMI and waist circumference, as 
markers of obesity, were not found. Future investi-
gations including larger cohorts of subjects, as 
well as studies in other populations, are needed to 
substantiate these fi ndings.
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Povezanost između polimorfi zama gena 11β-hidroksisteroidne 
dehidrogenaze tipa 1 i metaboličkog sindroma u Bosanskoj populaciji
Sažetak
Uvod: Enzim 11β-hidroksisteroidne dehidrogenaza tipa 1 (engl. 11β-hydroxysteroid dehydrogenase type 1, 11β-HSD1) katalizira pretvorbu hor-
monalno neaktivnog kortizona u aktivan kortizol te na taj način omogućuje aktivaciju receptora glukokortikoda u ciljnim tkivima. Povišena eks-
pre sija 11β-HSD1 u adipoznom tkivu povezuje se s pretilošću i inzulinskom rezistencijom. U ovom istraživanju ispitivali smo povezanost dvaju 
polimorfi zma gena 11β-HSD1 (HSD11B1) s metaboličkim sindromom (MetS) i njegovim karakteristikama u Bosanskoj populaciji.
Materijali i metode: U istraživanje je bilo uključeno 86 ispitanika: 43 bolesnika s dijagnozom metaboličkog sindroma i 43 zdrava ispitanika. 
Načinjena je genotipizacija analizom krivulje taljenja DNK visoke rezolucije za dva polimorfi zma gena HSD11B1: rs846910:G>A i rs45487298:insA. 
Ispitana je i raspodjela genotipova te utjecaj genotipova na kliničke i biokemijske parametre.
Rezultati: Nije nađena statistički značajna razlika u frekvencijama mutiranih alela za dva polimorfi zma gena HSD11B1 između skupina bolesnika s 
MetS i kontrolnih ispitanika. Kod bolesnika s MetS nisu primijećene statistički značajne veze između značajki povezanih s bolešću i rqs45487298: insA. 
Što se tiče polimorfi zma rs846910: G>A, heterozigotni su bolesnici (G/A) imali statistički značajno niži sistolički (P = 0,017) i dijastolički (P = 0,015) 
krvni tlak, niži HOMA-IR indeks (P = 0,011) i višu koncentraciju LDL-kolesterola (P = 0.049) u usporedbi s divljim tipom. U skupini zdravih ispitanika 
polimorfi zam rs45487298: insA bio je povezan s nižim koncentracijama inzulina natašte (P = 0,041), nižim homeostatskim modelom procjene inzu-
linske rezistencije - HOMA-IR indeksom (P = 0,041) i nižim dijastoličkim tlakom (P = 0,048). Značajne razlike između rs846910: G>A genotipova kod 
kontrola nisu nađene . Analiza halotipova potvrdila je povezanost rs45487298: insA s biljezima inzulinske rezistencije kod kontrolnih ispitanika.
Zaključak: Naši rezultati pokazuju da čest polimorfi zam rs45487298: insA gena HSD11B1 može imati zaštitni učinak protiv inzulinske rezistencije.
Ključne riječi: metabolički sindrom; inzulinska rezistencija; pretilost; 11-beta-hidroksisteroid dehidrogenaza tipa 1; genetički polimorfi zam; 
analiza krivulje taljenja DNK visoke rezolucije
